Browse News
Filter News
Found 234 articles
-
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
3/11/2024
Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.
-
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
3/7/2024
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma.
-
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
3/7/2024
A pioneering Phase 1 CAR T cell therapy trial for the treatment of glioblastoma at City of Hope, one of the largest cancer treatment and research organizations in the United States, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.
-
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
1/11/2024
Mustang Bio, Inc. today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference.
-
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
12/11/2023
Mustang Bio, Inc. today announced updated encouraging safety and efficacy data from Mustang’s multicenter Phase 1/2 clinical trial of MB-106, a CD20-targeted, 3rd-generation autologous CAR T-cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”).
-
Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
11/14/2023
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2023.
-
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
11/14/2023
Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO) today announced financial results and recent corporate highlights for the third quarter that ended September 30, 2023.
-
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
11/2/2023
Mustang Bio, Inc. announced that interim Phase 1/2 data from Mustang’s multicenter clinical trial of MB-106, a CD20-targeted, autologous CAR-T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, have been selected for a poster presentation at the 65th American Society of Hematology Annual Meeting, taking place December 9-12, 2023 in San Diego.
-
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
10/30/2023
Mustang Bio, Inc. announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the purchase and sale of 2,588,236 of its shares of common stock at a purchase price of $1.70 per share.
-
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
10/26/2023
Mustang Bio, Inc. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,588,236 of its shares of common stock at a purchase price of $1.70 per share in a registered direct offering priced at-the-market under Nasdaq rules.
-
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
10/26/2023
Mustang Bio, Inc. announced that the U.S. Food and Drug Administration has accepted the Company’s Investigational New Drug application of MB-109 for the treatment of recurrent glioblastoma and high-grade astrocytoma.
-
Mustang Bio to Participate in Upcoming September 2023 Investor Conferences
9/7/2023
Mustang Bio, Inc. announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City.
-
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
8/16/2023
Mustang Bio, Inc. today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHL”) and chronic lymphocytic leukemia
-
Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
8/14/2023
Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO) today announced financial results and recent corporate highlights for the second quarter ended June 30, 2023.
-
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
8/14/2023
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) today announced financial results and recent corporate highlights for the second quarter ended June 30, 2023.
-
Mustang Bio to Participate in Two August 2023 Investor Conferences
8/3/2023
Mustang Bio, Inc. today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two investor conferences in August 2023.
-
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
7/31/2023
Mustang Bio, Inc. today announced that, on July 28, 2023, it amended its previously announced asset purchase agreement with uBriGene (Boston) Biosciences Inc.
-
Mustang Bio Announces Participation in Upcoming Scientific Meetings - July 06, 2023
7/6/2023
Mustang Bio, Inc. announced that members of its management team will participate in the 2ndIn Vivo Engineering of Therapeutic Cells Summit, scheduled to take place from July 10-12, 2023, and the 8th Annual CAR-TCR Summit, scheduled to take place from August 29 – September 1, 2023, both in Boston, MA.
-
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
6/15/2023
Mustang Bio, Inc. announced that final data from the follicular lymphoma cohort of the single-institution Phase 1/2 clinical trial of MB-106 demonstrate treatment with the CD20-targeted, autologous CAR T-cell therapy resulted in high overall response and complete response rates and CAR T persistence in FL patients.
-
Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
6/12/2023
Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, show a favorable safety and efficacy profile in patients with Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer.